Back to discover
Drug

Noscapine

In clinical development
Emerging researchEarly-to-mid development

Also known as (-)-narcotine, alpha-Narcotine, Noscapina, Noscapinum.

1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Noscapine
Aliases & brands
(-)-narcotinealpha-NarcotineNoscapinaNoscapinum
RxNorm CUI
7533
ChEMBL ID
CHEMBL364713
ATC codes
R05DA07
UNII
8V32U4AOQU

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
1
Discontinued
PHASE DISTRIBUTIONn = 1
Phase 1 / 21

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential
Recent papers
Major research themes3
Alzheimer Disease1Edaravone1Noscapine1
Journals, researchers & institutions
Top journals
  • Experimental aging research1
Leading researchers
  • Doshi GM1
  • Godad AP1
  • Hafizur Rehman MR1
Leading institutions
free-text, unnormalised
  • SVKM's Dr Bhanuben Nanavati College of Pharmacy1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 2 of the same disease areas as Noscapine in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials